Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression
Gene expression related to fatty liver of CAR+/+ and CAR-/- mice after 12 weeks of pioglitazone treatment in chow and high-fat diet condition. (a) Difference in expression of genes involved in lipogenesis, SREBP-1c, FAS, and SCD-1, and lipid uptake, CD36 and MTTP. (b) Difference in expression of PPARs and PGC1α and genes involved in fatty acid oxidation, CPT1α, LCAD, and CYP4A14. p < 0.05. CD36, cluster of differentiation 36; CPT1α, carnitine palmitoyltransferase 1α; CYP4A14, cytochrome P450, family 4, subfamily a, polypeptide 14; FAS, fatty acid synthase; LCAD, long-chain acyl-CoA dehydrogenase; MTTP, microsomal triglyceride transfer protein; PGC1α, peroxisome proliferator-activated receptor γ coactivator 1α; PPAR, peroxisome proliferator-activated receptor; SREBP-1c, sterol-regulatory element binding protein-1c; SCD-1, stearoyl-CoA desaturase.